Introduction 1
Mast cell tumours (MCT) are the most common skin malignancy in dogs and are thought to 2 arise from neoplastic transformation of tissue mast cells, although the precise aetiology is 3 uncharacterised (reviewed by Dobson and Scase, 2007, Welle et al., 2008) . In order to 4 become malignant, mast cells must be able to resist those mechanisms associated with 5 programmed cell death, to allow survival and proliferation. Developing a greater 6 understanding of how such cells prevent apoptosis might enable us to design more rational 7 treatment strategies for this type of cancer. 8
Mast cell viability in healthy tissues is regulated by stem cell factor (SCF) via its 9 action on the KIT receptor (CD117), which has tyrosine kinase activity (Qiu et al., 1988) . 10 SCF binding to KIT is thought to provide survival signals, by inhibiting apoptosis through 11 modulation of apoptosis-regulatory proteins (Kitamura et al., 1978 , Kitamura & Go, 1979 , 12 Galli & Kitamura, 1987 , Tsai et al., 1991 , Galli et al., 1994 , Serve et al., 1995 , Linnekin et 13 al., 1997 , Vosseller et al., 1997 , Timokhina et al., 1998 , Brazis et al., 2000 , Taylor & 14 Metcalfe, 2000 . In human mast cells, overexpression of Bcl-2 or Bcl-x L, protects against 15 programmed cell death and is thought to contribute to oncogenesis (Cerveró et al., 1999 , 16 Hartmann et al., 2003 . Mutations in the KIT gene are found in 15-50% of canine MCT, 17 which typically consist of in-tandem duplications, located in or around exon 11 (London et 18 al., 1999 , Ma et al., 1999 , Reguera et al., 2000 , Downing et al., 2002 , Reguera et al., 2002 , 19 Zemke et al., 2002 , Turin et al 2006 , Webster et al., 2006 . When expressed, such 20 mutations often result in autophosphorylation of the cytoplasmic kinase domain of the 21 receptor protein, leading to constitutive activation, even in the absence of SCF (London et 22 al., 1999 , Ma et al., 1999 , Pryer et al., 2003 . The C2 mastocytoma cell line, which is 23 commonly used to study canine malignant mast cell biology in vitro, expresses a 48 base-24 pair in-tandem duplication (London et al., 1999 , Ma et al., 1999 , although the preciselocation, nature and size of mutations can vary between different MCTs (Reguera et al., 1 2000 , Downing et al., 2002 , Pryer et al., 2003 , Riva et al., 2005 , Roskoski et al., 2005 , Turin 2 et al., 2006 , Webster et al., 2006A, Letard et al., 2008 . 3 KIT activating mutations have been shown to be associated with MCT of a more 4 aggressive phenotype, which is likely due to increased proliferation and resistance to 5 apoptosis (Hirota et al., 1998 , Corless et al., 2004 , Gleixner et al., 2007 , Webster et al., 6 2007 , Letard et al., 2008 . This has led to several investigations into the therapeutic 7 potential of receptor tyrosine kinase inhibitors (RTKi), designed to specifically target this 8 molecule. There are currently two drugs (masitinib, Masivet ® , AB Science; toceranib, 9 Palladia ® , Pfizer) that have recently been licensed for canine MCT. However, these 10 compounds can also impact on other receptor tyrosine kinases (Rubin et al., 2001 , Hayes & 11 Thor, 2002 , Humbert et al., 2009 , London et al., 2009 , potentially leading to adverse 12 effects. More specific targeting of the mutant KIT receptor is likely to be more selective in 13 having anti-cancer effects. 14 RNA interference can be used to target specific mRNA for degradation (Spee et al., 15 2006 , Tsuchiya et al., 2006 , Watanabe et al., 2009 . Thus, gene expression can be selectively 16 silenced, preventing production of the encoded protein, which allows experiments to be 17 designed to determine the role of that specific gene product on cellular function. The aim of 18 the current study was to determine whether small inhibitory RNA (SiRNA) molecules could 19 be designed to specifically knock-down canine KIT expression. In particular we aimed to 20 design novel SiRNA molecules that specifically targeted the mutant KIT expressed by C2 21 cells that would spare expression of the wild-type receptor. However, since C2 cells proved 22 to be resistant to chemical transfection, we used a reporter gene assay to assess the ability of 23 canine KIT-specific SiRNA molecules to knock-down their target. 24 1
Materials and Methods 2

Plasmid DNA constructs and SiRNA molecules 3
Partial coding regions for selected canine genes were amplified by PCR from cDNA prepared 4 from the C2 canine mastocytoma cell line (a generous gift from Dr B. Helm, University of 5 Sheffield; originally generated by Prof W. Gold, University of California (Lazarus et al., 6 1986), which expresses both wild-type KIT as well as a KIT exon 11 mutation (Figure 1) were initially cloned into the pSC-A vector (Stratagene, La Jolla, CA). Plasmid DNA from 16 recombinant clones was sequenced to confirm the integrity of the inserts, which were then 17 sub-cloned into the psi-CHECK™-2 bi-cistronic vector (Promega, Southampton, UK), 18 downstream of the renilla luciferase element using NotI and XhoI restriction sites. Plasmid 19 DNA was then extracted from recombinant E.coli using the GenElute™ Endotoxin-free 20
Miniprep Kit (Sigma, Poole, UK) in preparation for transfection studies. The SiRNA 21 molecules used in the study are shown in Table 1 . In addition, a scrambled SiRNA molecule 22 (AllStars Negative Control SiRNA, Qiagen, Crawley, UK) was used as a negative control. 
Results 23
Knock-down in expression of canine housekeeping genes and KIT wild-type
Since there are few studies using SiRNA to specifically knock-down canine gene expression, 1 several SiRNA molecules were initially assessed that were designed to target housekeeping 2 genes. Using a renilla luciferase SiRNA molecule as a positive control, efficient knock-down 3 of canine GAPDH was demonstrated, although SiRNA molecules targeting beta-2 4 microglobulin were less efficient (Table 2) . A validated human KIT SiRNA molecule (which 5 has complete identity to the target sequence in canine KIT) was evaluated and showed >90% 6 knock-down efficiency (Table 2) . 7 8
Knock-down in expression of the C2 KIT mutant 9
The mutation present in the KIT gene expressed by C2 cells consists of a 48 bp in-tandem 10 duplication in exon 11. Since this generates a unique sequence at the 5' junction of the 11 insertion, an SiRNA molecule was designed that spanned this region (Figure 1 , Table 1 ). 12
When tested against constructs containing either the wild-type sequence or the mutant 13 version, this SiRNA molecule demonstrated efficient knock-down when using the KIT2 mutant 14 construct (mean 93.1% knock-down) but had little effect on the KIT2
wild-type construct (mean -15 2.98% knock-down) (Figure 2) . 16 17
Discussion 18
Recent advances in treatment of canine MCT have focused on the use of RTKi (e.g 19 masitinib and toceranib). However, these compounds are not specific for KIT and also inhibit 20 other receptor tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR) and 21 vascular growth factor receptor (VEGFR2) (Rubin et al., 2001 , Hayes & Thor, 2002 , Humbert 22 et al., 2009 , London et al., 2009 . Although the lack of specificity might enhance the anti-23 cancer efficacy of these drugs, this could also increase the risk of adverse effects in the 24 patient. In addition, these RTKi will not have specific effects on malignant mast cells, as theywill also inhibit wild-type KIT, expressed by tissue mast cells and other cell types including 1 haematopoietic stem cells and melanocytes (Galli et al., 1994 , Serve et al., 1995 The KIT exon2 SiRNA molecule is not specific to the mutant KIT sequence and would 22 be expected to knock-down both wild-type and mutant KIT mRNAs. Therefore, a novel 23 canine KIT SiRNA molecule was designed, that targeted the 5' junction of the insertion 24 mutation to determine whether it might be possible to specifically knock-down the mutant 25 version, while sparing expression of wild-type KIT. Both firefly and renilla luciferase activity 1 were consistently lower when using the psiCHECK-2 TM construct containing canine mutant 2 KIT, compared to the native vector or vector containing wild-type KIT sequences. Endotoxin 3 contamination of the plasmid DNA was considered, but a new batch of plasmid DNA 4 demonstrated the same response. The explanation for this reduced efficiency of luciferase 5 activity with this particular construct remains unclear. Despite this, the KIT exon11mut SiRNA 6 molecule demonstrated specificity of activity against the mutant KIT construct, without 7 affecting expression from the construct containing the equivalent wild-type KIT sequence. 8
In the current study, we have validated several canine gene-specific SiRNA 9 molecules. These can now be assessed in canine cell lines and it is anticipated that alternative 10 delivery systems (e.g. electroporation) will allow evaluation of these molecules in the C2 cell 11 line. We have shown as "proof-of-concept" that SiRNA molecules can be designed to 12 specifically target KIT mutations, although the heterogeneity of mutations seen in canine 13
MCT means that it is unlikely that a single SiRNA molecule could be designed that would be 14 effective in all cases. 15 Table 2 . Knockdown efficiency of canine housekeeping gene and KIT SiRNA molecules. Triplicate wells of CHO cells were transfected with native or recombinant psiCHECK-2 plasmid DNA and co-transfected with either scrambled siRNA, siRNA targeted to renilla luciferase, or SiRNA targeting the inserted canine sequence. Both firefly and renilla luciferase activity were measured after 24 h incubation. Mean luminescence data are shown, following subtraction of the luminescence values of untransfected CHO cells. Knockdown efficiency of targeted siRNA was calculated compared to scrambled siRNA. GAPDH = glyceraldehyde-3-phosphate dehydrogenase, B2M = 2microglobulin, Exp = experimental replicate, LU = luminescence units, KD (%) = percentage knockdown efficiency. 
